Videos

From AI-powered prescription fulfillment to the expansion of PillPack for Medicare patients, Carey outlines how Amazon Pharmacy is streamlining access, improving affordability, and setting the stage for a more patient-centered health care future.

Panelists discuss how the patient journey with tardive dyskinesia involves evolving awareness and management of symptoms alongside underlying psychiatric conditions, highlighting the distinct needs of younger vs older patients and the essential role of pharmacists in supporting individualized, function-focused care throughout the lifespan.

Panelists discuss how extended-release VMAT2 inhibitor formulations improve adherence and tolerability through once-daily dosing and easier administration options, while emphasizing the importance of tailoring treatment to patient needs and the promise of emerging therapies in the pipeline.

UPMC's integrated approach to COPD care enhances patient outcomes through personalized support, coordinated services, and effective pulmonary rehabilitation strategies.

An expert discusses how pharmacists play a crucial role in managing tyrosine kinase inhibitor toxicities through proactive monitoring strategies, patient education about adverse effects such as myelosuppression and fluid retention, and early intervention protocols to maintain treatment adherence and quality of life.

An expert discusses how traditionally later-line therapies such as ponatinib and asciminib are now being reconsidered for earlier use, with asciminib approved for frontline treatment and ponatinib potentially used as second-line therapy for patients with specific mutations or comorbidities.

An expert discusses how pharmacists can ensure completion of multidose pneumococcal vaccine series through electronic reminder systems, state immunization registries, scheduled follow-up appointments, and providing patients with printed vaccine cards for tracking purposes.

Adam James, PharmD, and Chris Altman, PharmD, discuss renewed public scrutiny of thimerosal, its limited use in vaccines today, and how new guidance may affect pharmacists and patient confidence moving forward.

Millions of seniors and Medicare beneficiaries managing chronic conditions have new options for medication delivery and adherence support.

Debra Patt, MD, PhD, MBA; and Houston Holmes, MD, discuss the ramifications of the FDA's removal of REMS requirements for approved chimeric antigen receptor (CAR) T-cell (CAR T) therapies.

BCPPs can address behavioral health workforce shortages and advocate for expanded access and reimbursement amid evolving legislation and treatment landscapes.

Panelists discuss how initiating VMAT2 inhibitors for tardive dyskinesia requires careful consideration of factors like cost, patient tolerance, organ function, and drug interactions. They emphasize gradual dosing and shared decision-making to balance symptom control with adverse effect management in a personalized treatment approach.

Panelists discuss how personalizing tardive dyskinesia treatment involves a patient-centered approach that balances symptom impact, medication optimization, and comorbid psychiatric management—utilizing VMAT2 inhibitors alongside careful monitoring and collaboration among clinicians and pharmacists to tailor dosing and improve quality of life.

Keri Bates, PharmD, shares how the nomination validates years of hard work, highlights the deep relationships built with the community, and inspires continued growth and innovation.

Empowering pharmacy technicians enhances team efficiency, improves patient care, and fosters a positive work culture, driving pharmacy success in a competitive landscape.

These health care professionals are crucial to optimizing safety in medication therapy, addressing policy barriers, and the collaboration with others in the field.

Panelists discuss how pharmacists play a crucial role in biliary tract cancer management by leveraging their detailed medication knowledge to assist with treatment selection, develop comprehensive monitoring plans (especially for hyperphosphatemia with FGFR inhibitors and cardiac monitoring with HER2 therapies), educate patients about unique toxicities and self-management strategies, create clinic workflow algorithms for toxicity management, and advocate for maximizing time on therapy as long as patients maintain response or stable disease given the limited treatment options available for this rare cancer type.

Panelists discuss how trastuzumab deruxtecan demonstrated a 22% overall response rate in patients with biliary tract cancer (56.3% in HER2 3+ patients) with 7.4 months progression-free survival in the tumor-agnostic DESTINY-PanTumor02 trial, while zanidatamab showed a 52% confirmed response rate with 7.2 months progression-free survival in HER2 3+ patients in the biliary-specific HERIZON-BTC-01 trial, with treatment selection between these agents requiring individualized case-by-case decisions based on toxicity profiles, dosing schedules, and patient-specific factors since no head-to-head comparison data exist.

Panelists discuss how HER2-targeted agents in biliary tract cancers include trastuzumab deruxtecan (an antibody-drug conjugate that acts like a “smart missile” delivering cytotoxic payload to HER2-expressing cells with risks of pneumonitis and myelosuppression) and zanidatamab (a bispecific antibody targeting 2 different HER2 epitopes simultaneously for enhanced cytotoxicity with primarily antibody-related toxicities like cardiac effects and diarrhea but without chemotherapy-related adverse effects).

Panelists discuss how first-line treatment typically involves gemcitabine-based cytotoxic chemotherapy (particularly gemcitabine with cisplatin) that has evolved to include chemo-immunotherapy combinations with checkpoint inhibitors like durvalumab and pembrolizumab, while second-line options include FOLFOX and targeted therapies based on specific mutations, with detailed focus on FGFR2 inhibitors like pemigatinib and futibatinib, which show promising response rates (35%-42%) but require careful monitoring for unique adverse effects including hyperphosphatemia and dermatologic toxicities.

Panelists discuss how comprehensive next-generation sequencing is performed to identify key biomarkers including IDH1/2 mutations and FGFR2 fusions (predominantly in intrahepatic cholangiocarcinoma), HER2 amplifications (common in gallbladder cancers), and other actionable alterations like BRAF V600E mutations, with NCCN guidelines recommending testing for specific biomarkers to guide targeted therapy decisions and clinical trial enrollment given the rarity of biliary tract cancers and limited treatment options.

The long-term outcomes from the CARTITUDE-1 trial in multiple myeloma and durable complete response data from the STARGLO trial in diffuse large B-cell lymphoma can be significant for these disease states.

Panelists discuss how biliary tract cancers represent a rare but serious disease state with approximately 41,000 new cases annually in the US, associated with inflammatory conditions like gallstones and primary sclerosing cholangitis, presenting with nonspecific symptoms except for jaundice in extrahepatic cases, and carrying a poor prognosis with only 10% to 20% 5-year overall survival rates across all stages.

Bates' insights offer a roadmap for creating a sustainable pharmacy workforce while strengthening patient care and operational efficiency.

Panelists discuss the evolving management of RSV, highlighting the importance of increasing awareness and education, anticipating advances in testing, data reporting, and treatment options like monoclonal antibodies and antivirals, and considering future vaccination strategies such as booster doses to enhance prevention and patient outcomes.

Panelists discuss strategies to address patient hesitancy around receiving multiple vaccines—flu, COVID-19, and RSV—simultaneously during the fall, emphasizing CDC recommendations for co-administration, educating patients about manageable adverse effects, tailoring conversations to individual concerns, and encouraging year-round RSV vaccination to maximize protection and reduce missed opportunities.

Panelists discuss how community pharmacies have become trusted hubs for adult vaccinations, with pharmacists not only administering vaccines but also educating patients and coordinating with other health care providers to ensure clear, unified messaging; they emphasize the importance of collaboration, empowering pharmacists to use clinical judgment, and actively navigating insurance challenges to improve vaccine access and public health outcomes.